Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer

[1] Ferlay J(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 1374-1403

[2] Steliarova-Foucher E(2016)Risk of brain metastases in patients with nonmetastatic lung cancer: analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data Cancer 122 1921-1927

[3] Lortet-Tieulent J(2016)The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer Cancer Treat Rev 45 139-162

[4] Goncalves PH(2006)EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force Eur J Neurol 13 674-681

[5] Peterson SL(2016)Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 27 v1-v27

[6] Vigneau FD(2015)Response assessment criteria for brain metastases: proposal from the RANO group Lancet Oncol 16 e270-e278

[7] Peters S(2016)The predictive capacity of apparent diffusion coefficient (ADC) in response assessment of brain metastases following radiation Clin Exp Metastasis 33 277-284

[8] Bexelius C(2003)Assessment of brain metastases with dynamic susceptibility-weighted contrast-enhanced MR imaging: initial results Radiology 228 193-199

[9] Munk V(2009)Dynamics of metabolic changes in intracranial metastases and distant normal-appearing brain tissue after stereotactic radiosurgery: a serial proton magnetic resonance spectroscopy study Neuroradiol J 22 58-71

[10] Leighl N(2013)Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications NMR Biomed 26 1042-1049

[1] Ferlay J(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 1374-1403

[2] Steliarova-Foucher E(2016)Risk of brain metastases in patients with nonmetastatic lung cancer: analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data Cancer 122 1921-1927

[3] Lortet-Tieulent J(2016)The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer Cancer Treat Rev 45 139-162

[4] Goncalves PH(2006)EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force Eur J Neurol 13 674-681

[5] Peterson SL(2016)Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 27 v1-v27

[6] Vigneau FD(2015)Response assessment criteria for brain metastases: proposal from the RANO group Lancet Oncol 16 e270-e278

[7] Peters S(2016)The predictive capacity of apparent diffusion coefficient (ADC) in response assessment of brain metastases following radiation Clin Exp Metastasis 33 277-284

[8] Bexelius C(2003)Assessment of brain metastases with dynamic susceptibility-weighted contrast-enhanced MR imaging: initial results Radiology 228 193-199

[9] Munk V(2009)Dynamics of metabolic changes in intracranial metastases and distant normal-appearing brain tissue after stereotactic radiosurgery: a serial proton magnetic resonance spectroscopy study Neuroradiol J 22 58-71

[10] Leighl N(2013)Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications NMR Biomed 26 1042-1049